These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38946401)

  • 1. Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    Yu H; Huang Y; Li M; Jiang H; Yang B; Xi X; Smayi A; Wu B; Yang Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2169-2181. PubMed ID: 38946401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
    Gawrieh S; Vilar-Gomez E; Wilson LA; Pike F; Kleiner DE; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Kowdley KV; Hameed B; Tonascia J; Loomba R; Sanyal AJ; Chalasani N;
    J Hepatol; 2024 Oct; 81(4):600-608. PubMed ID: 38762169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
    Zhou XD; Kim SU; Yip TC; Petta S; Nakajima A; Tsochatzis E; Boursier J; Bugianesi E; Hagström H; Chan WK; Romero-Gomez M; Calleja JL; de Lédinghen V; Castéra L; Sanyal AJ; Goh GB; Newsome PN; Fan J; Lai M; Fournier-Poizat C; Lee HW; Wong GL; Armandi A; Shang Y; Pennisi G; Llop E; Yoneda M; Saint-Loup M; Canivet CM; Lara-Romero C; Gallego-Duràn R; Asgharpour A; Teh KK; Mahgoub S; Chan MS; Lin H; Liu WY; Targher G; Byrne CD; Wong VW; Zheng MH;
    Gut; 2024 Oct; 73(11):1883-1892. PubMed ID: 39089860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
    Thorhauge KH; Semmler G; Johansen S; Lindvig KP; Kjærgaard M; Hansen JK; Torp N; Hansen CD; Andersen P; Hofer BS; Gu W; Israelsen M; Mandorfer M; Reiberger T; Trebicka J; Thiele M; Krag A;
    J Hepatol; 2024 Jul; 81(1):23-32. PubMed ID: 38428644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    Papatheodoridi M; De Ledinghen V; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; Delamarre A; Pinzani M; Tsochatzis EA
    J Hepatol; 2024 Oct; 81(4):590-599. PubMed ID: 38789011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
    Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.
    Kim SU; Lee JH; Kim DY; Ahn SH; Jung KS; Choi EH; Park YN; Han KH; Chon CY; Park JY
    PLoS One; 2012; 7(5):e36676. PubMed ID: 22574212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
    Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H
    J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
    Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
    Semmler G; Yang Z; Fritz L; Köck F; Hofer BS; Balcar L; Hartl L; Jachs M; Stopfer K; Schedlbauer A; Neumayer D; Maurer J; Müllner-Bucsics T; Simbrunner B; Scheiner B; Trauner M; Mandorfer M; Reiberger T; Bauer DJM
    Gastroenterology; 2023 Oct; 165(4):1041-1052. PubMed ID: 37442301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    Semmler G; Alonso López S; Pons M; Lens S; Dajti E; Griemsmann M; Zanetto A; Burghart L; Hametner-Schreil S; Hartl L; Manzano M; Rodriguez-Tajes S; Zanaga P; Schwarz M; Gutierrez ML; Jachs M; Pocurull A; Polo B; Ecker D; Mateos B; Izquierdo S; Real Y; Ahumada A; Bauer DJM; Mauz JB; Casanova-Cabral M; Gschwantler M; Russo FP; Azzaroli F; Maasoumy B; Reiberger T; Forns X; Genesca J; Bañares R; Mandorfer M;
    J Hepatol; 2024 Jul; 81(1):76-83. PubMed ID: 38521170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B.
    Wong GL; Chan HL; Yu Z; Wong CK; Leung C; Ho PP; Chan CY; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2015 Mar; 30(3):582-90. PubMed ID: 25252074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
    Pennisi G; Enea M; Pandolfo A; Celsa C; Antonucci M; Ciccioli C; Infantino G; La Mantia C; Parisi S; Tulone A; Di Marco V; Craxì A; Cammà C; Petta S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1293-1302.e5. PubMed ID: 35842119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
    Wu S; Kong Y; Piao H; Jiang W; Xie W; Chen Y; Lu L; Ma A; Xie S; Ding H; Shang J; Zhang X; Feng B; Han T; Xu X; Huo L; Cheng J; Li H; Wu X; Zhou J; Sun Y; Ou X; Zhang H; You H; Jia J
    Liver Int; 2018 Jun; 38(6):1045-1054. PubMed ID: 29119705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
    J Hepatol; 2024 Aug; 81(2):248-257. PubMed ID: 38479612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    Corpechot C; Carrat F; Gaouar F; Chau F; Hirschfield G; Gulamhusein A; Montano-Loza AJ; Lytvyak E; Schramm C; Pares A; Olivas I; Eaton JE; Osman KT; Dalekos G; Gatselis N; Nevens F; Cazzagon N; Zago A; Russo FP; Abbas N; Trivedi P; Thorburn D; Saffioti F; Barkai L; Roccarina D; Calvaruso V; Fichera A; Delamarre A; Medina-Morales E; Bonder A; Patwardhan V; Rigamonti C; Carbone M; Invernizzi P; Cristoferi L; van der Meer A; de Veer R; Zigmond E; Yehezkel E; Kremer AE; Deibel A; Dumortier J; Bruns T; Große K; Pageaux GP; Wetten A; Dyson J; Jones D; Chazouillères O; Hansen B; de Lédinghen V;
    J Hepatol; 2022 Dec; 77(6):1545-1553. PubMed ID: 35777587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
    Papatheodoridi M; Hiriart JB; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; de Ledinghen V; Pinzani M; Tsochatzis EA
    J Hepatol; 2021 May; 74(5):1109-1116. PubMed ID: 33307138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease.
    Pons M; Simón-Talero M; Millán L; Ventura-Cots M; Santos B; Augustin S; Genescà J
    Dig Liver Dis; 2016 Oct; 48(10):1214-9. PubMed ID: 27388262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.